FibroBiologics (NASDAQ:FBLG) Receives Buy Rating from D. Boral Capital

FibroBiologics (NASDAQ:FBLG)‘s stock had its “buy” rating reaffirmed by D. Boral Capital in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $16.00 price objective on the stock.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $12.00 price objective (up from $10.00) on shares of FibroBiologics in a report on Tuesday, August 5th. Four equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $13.00.

FibroBiologics Stock Performance

Shares of NASDAQ FBLG opened at $0.56 on Wednesday. The business’s 50-day simple moving average is $0.61 and its 200-day simple moving average is $0.83. FibroBiologics has a 52 week low of $0.53 and a 52 week high of $4.14. The firm has a market cap of $23.66 million, a price-to-earnings ratio of -1.57 and a beta of -0.73.

FibroBiologics (NASDAQ:FBLG) last announced its earnings results on Thursday, July 31st. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). As a group, equities research analysts forecast that FibroBiologics will post -0.53 earnings per share for the current year.

Institutional Trading of FibroBiologics

A number of hedge funds have recently bought and sold shares of FBLG. Jane Street Group LLC bought a new stake in shares of FibroBiologics in the 2nd quarter worth approximately $60,000. Cerity Partners LLC raised its stake in shares of FibroBiologics by 37.2% in the second quarter. Cerity Partners LLC now owns 128,109 shares of the company’s stock valued at $80,000 after purchasing an additional 34,702 shares in the last quarter. Marshall Wace LLP bought a new position in FibroBiologics in the second quarter worth $49,000. XTX Topco Ltd boosted its stake in FibroBiologics by 160.0% during the second quarter. XTX Topco Ltd now owns 45,945 shares of the company’s stock worth $29,000 after buying an additional 28,276 shares in the last quarter. Finally, Cascade Financial Partners LLC increased its holdings in FibroBiologics by 11.7% in the 2nd quarter. Cascade Financial Partners LLC now owns 290,581 shares of the company’s stock valued at $181,000 after buying an additional 30,500 shares during the period.

About FibroBiologics

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.